In molecular testing, we analyzed common genetic alterations to FTA, FTC, PTC, HTT, PDTC, and MTC [3] using the next-generation sequencing custom targeted panel (Ion Torrent Genexus, Thermo Fisher Sci., MA, USA), including point mutations in BRAF, N/K/H-RAS, RET, TERT promoter, EIF1AX, AKT1, CTNNB1, PTEN, etc. We also analyzed the presence of PAX8/GLIS1 and PAX8/GLIS3 fusion genes, which are hallmarks of HTT, using RT-PCR (Nikiforova MN et al., PMID: 30,648,929). This evidence concerns the gene RET and medullary thyroid gland carcinoma.